Bremelanotide for female sexual dysfunctions in premenopausal women: A randomized, placebo-controlled dose-finding trial

Anita H. Clayton, Stanley E. Althof, Sheryl Kingsberg, Leonard R. Derogatis, Robin Kroll, Irwin Goldstein, Jed Kaminetsky, Carl Spana, Johna Lucas, Robert Jordan, David J. Portman

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: Evaluate efficacy/safety of bremelanotide (BMT), a melanocortin-receptor-4 agonist, to treat female sexual dysfunctions in premenopausal women. Methods: Patients randomized to receive placebo or BMT 0.75, 1.25 or 1.75 mg self-administered subcutaneously, as desired, over 12 weeks. Primary end point was change in satisfying sexual events/month. Secondary end points included total score changes on female sexual function index and female sexual distress scale-desire/arousal/orgasm. Results: Efficacy data, n = 327. For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), -11.1 versus -6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014). Adverse events: nausea, flushing, headache. Conclusion: In premenopausal women with female sexual dysfunctions, self-administered, as desired, subcutaneous BMT was safe, effective, and well tolerated (NCT01382719).

Original languageEnglish (US)
Pages (from-to)325-337
Number of pages13
JournalWomen's Health
Volume12
Issue number3
DOIs
StatePublished - Jun 2016
Externally publishedYes

Keywords

  • FSD
  • HSDD
  • bremelanotide
  • female sexual arousal disorder
  • female sexual dysfunction
  • hypoactive sexual desire disorder

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Bremelanotide for female sexual dysfunctions in premenopausal women: A randomized, placebo-controlled dose-finding trial'. Together they form a unique fingerprint.

Cite this